Idiopathic Pulmonary Fibrosis (IPF), a progressively destructive lung disease caused by unchecked fibroblast activity and uncontrolled formation of pulmonary scar tissue,[1] has a median survival from the time of diagnosis, just short of 3 years. The recently approved anti-fibrotic drugs, pirfenidone and nintedanib, are effective in altering disease progression.[2,3] Therefore, increasing clinical awareness and earlier detection of the disease process have become important goals to achieve.[4] Currently, no useful clinical tools exist for the efficient screening and early detection of IPF.
